Current Report Filing (8-k)
December 06 2018 - 5:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8‑K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: December 3, 2018
Commission File Number
000-53230
PEPTIDE TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
98-0479983
|
State or other jurisdiction of
|
|
(I.R.S. Employer
|
incorporation or organization
|
|
Identification No.)
|
5348 Vegas Drive #177 Las Vegas, NV 89108
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (702) 948-8893
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Resignation of Director and Officer
Effective December 3, 2018, a letter of resignation tendered by Baxter Koehn as Director of the
Company, and as Chairman of the Board of Directors for the Company and as Chief Financial Officer, was
accepted. Upon his resignation, Baxter Koehn relinquished 45,000,000 shares of common stock to Irene
Getty upon her acceptance of the positions of Chief Financial for the Company.
Appointment of Officers
Effective December 3, 2018, Irene Getty has been appointed Chief Financial Officer of
the Company until she resigns or her successors be elected by the shareholders of the Company or appointed
by the Board of Directors. Irene Getty is also presently a member of the Board of Directors of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be
signed on its behalf by the undersigned, hereunto duly authorized.
|
PEPTIDE TECHNOLOGIES, INC.
|
By:
/s/
Bruce Sellars
Chairman of the Board
Date: December 4, 2018